177 related articles for article (PubMed ID: 21928258)
1. Triple therapy for corneal neovascularization: a case report.
Veritti D; Vergallo S; Lanzetta P
Eur J Ophthalmol; 2012; 22 Suppl 7():S126-8. PubMed ID: 21928258
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.
You IC; Im SK; Lee SH; Yoon KC
Cornea; 2011 Jan; 30(1):30-3. PubMed ID: 20861729
[TBL] [Abstract][Full Text] [Related]
3. [Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and/or photodynamic therapy].
Hamdan J; Boulze M; Aziz A; Alessi G; Hoffart L
J Fr Ophtalmol; 2015 Dec; 38(10):924-33. PubMed ID: 26522892
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
Augustin AJ; Schmidt-Erfurth U
Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
[TBL] [Abstract][Full Text] [Related]
5. Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy.
Sakai T; Ohkuma Y; Kohno H; Hayashi T; Watanabe A; Tsuneoka H
Br J Ophthalmol; 2014 Dec; 98(12):1642-8. PubMed ID: 25053762
[TBL] [Abstract][Full Text] [Related]
6. Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters.
Veritti D; Lanzetta P
Ophthalmologica; 2013; 230(3):131-7. PubMed ID: 23948986
[TBL] [Abstract][Full Text] [Related]
7. Comparison of photodynamic therapy with two different parameters combined with subconjunctival injection of bevacizumab for corneal neovascularization.
Yin XF; Wu MH; Jin CJ; Zhou SY
Photodiagnosis Photodyn Ther; 2024 Apr; 46():104067. PubMed ID: 38548042
[TBL] [Abstract][Full Text] [Related]
8. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.
Spaide RF; Sorenson J; Maranan L
Ophthalmology; 2005 Feb; 112(2):301-4. PubMed ID: 15691567
[TBL] [Abstract][Full Text] [Related]
10. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
Augustin AJ; Puls S; Offermann I
Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens-Johnson syndrome.
Yoon HJ; Kim MK; Seo KY; Ueta M; Yoon KC
Int Ophthalmol; 2019 Jan; 39(1):55-62. PubMed ID: 29256167
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab for graft rejection.
Harooni H; Reddy V; Root T; Ambati B
Ophthalmology; 2007 Oct; 114(10):1950. PubMed ID: 17908597
[No Abstract] [Full Text] [Related]
13. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
Spaide RF; Sorenson J; Maranan L
Ophthalmology; 2003 Aug; 110(8):1517-25. PubMed ID: 12917166
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration.
Kovacs KD; Quirk MT; Kinoshita T; Gautam S; Ceron OM; Murtha TJ; Arroyo JG
Retina; 2011 Mar; 31(3):446-52. PubMed ID: 21336068
[TBL] [Abstract][Full Text] [Related]
15. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.
Augustin AJ; Schmidt-Erfurth U
Am J Ophthalmol; 2006 Apr; 141(4):638-45. PubMed ID: 16564797
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor monotherapy versus combination treatment with photodynamic therapy for subfoveal choroidal neovascularization secondary to causes other than age-related macular degeneration.
Chen L; Miller JW; Vavvas D; Kim IK
Retina; 2011 Nov; 31(10):2078-83. PubMed ID: 21691258
[TBL] [Abstract][Full Text] [Related]
17. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
Bakri SJ; Couch SM; McCannel CA; Edwards AO
Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
[TBL] [Abstract][Full Text] [Related]
18. Choroidal neovascularization in sorsby fundus dystrophy treated with photodynamic therapy and intravitreal triamcinolone acetonide.
Peiretti E; Klancnik JM; Spaide RF; Yannuzzi L
Retina; 2005; 25(3):377-9. PubMed ID: 15805922
[No Abstract] [Full Text] [Related]
19. The efficacy of photodynamic therapy combined with intravitreal triamcinolone acetonide (TA) for treatment of occult choroidal neovascularization secondary to age-related macular degeneration.
Ho TC
Retina; 2006; 26(6):714; author reply 715. PubMed ID: 16829825
[No Abstract] [Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
